U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

ZOLIMIDINE

MORE DETAILS

  YCF001N8QB

Status:
Possibly Marketed Outside US
Source:
SOLIMIDIN by Selvi & C Lab Bioterapico
Source URL:
https://www.google.ch/patents/US3318880
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Peptic ulcer
72
Gastroesophageal reflux disease
68
Zolimidine, a derivate of imidazopyridine, has a gastroprotective effect. It is used in the treatment of peptic ulcer and gastro-oesophageal reflux disease.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966